These authors contributed equally to this work.
Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination
Article first published online: 21 OCT 2013
© 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 12, pages 1918–1934, December 2013
How to Cite
Syed, Y. A., Baer, A., Hofer, M. P., González, G. A., Rundle, J., Myrta, S., Huang, J. K., Zhao, C., Rossner, M. J., Trotter, M. W. B., Lubec, G., Franklin, R. J. M. and Kotter, M. R. (2013), Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol Med, 5: 1918–1934. doi: 10.1002/emmm.201303123
- Issue published online: 2 DEC 2013
- Article first published online: 21 OCT 2013
- Manuscript Accepted: 18 SEP 2013
- Manuscript Revised: 12 SEP 2013
- Manuscript Received: 3 JUN 2013
- Wings for Life
- Multiple Sclerosis Society
- BMBF. Grant Number: 01ES0812
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|emmm201303123.reviewer_comments.pdf||327K||Review Process File|
Fig. S1. Heat-map representation of some Mapk genes identified by microarray analysis.
Fig. S2. Creb1 activity increases during oligodendrocyte differentiation.
Fig. S3. Treatment with Pde4 inhibitors promote OPC differentiation in the presence of MAI.
Fig. S4. Quantification of apoptotic cells by TUNEL assay.
Fig. S5. Double immunohistochemistry conducted at the peak of the differentiation phase in remyelinating lesions (14 dpl) confirms expression of activated Erk1/2, p38Mapk and Creb1 in OPCs.
Fig. S6. Rolipram treatment does not change the size of the lesion.
Fig. S7. Experimental scheme and ranking analysis of remyelination.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.